newsfilter
← Latest News
PR Newswire·

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

BRUSSELS and ATLANTA, Sept. 29, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new interim results from the BE BRIGHT open-label extension (OLE) study evaluating the long-term safety, tolerability and efficacy of bimekizuma